Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations
Antimicrobial Agents and Chemotherapy · 03.09.2025 · 69 (9)
DOI: 10.1128/aac.00533-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.09.2025. Verfasst von Lucía Sánchez-Peña und 17 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Sp…. Hauptthemen laut MEDLINE: Meropenem, beta-Lactamases, beta-Lactamase Inhibitors, Anti-Bacterial Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Axencia Galega de Innovación.
Abstract (Originalsprache)
Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC 50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
- CIBER de Enfermedades Infecciosas, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
- Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Division of Intensive Care, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
- Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Laboratorio de Referencia para Tipado Molecular y Detección de Mecanismos de Resistencia a Antimicrobianos de Andalucía (PIRASOA), Unidad de Gestión Clínica de Microbiología y Enfermedades Infecciosas, Hospital Universi…
ORCID-Profile: Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, Tania Blanco-Martín, Lucía González-Pinto, Gloria Pérez-Rodríguez, Christophe Le Terrier, Inés Portillo-Calderón, Esther Recacha, Cristina Riazzo, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Belén Aracil, Laurent Poirel, Germán Bou, Jorge Arca-Suárez
Förderung
- Instituto de Salud Carlos III
- Axencia Galega de Innovación
Zitieren
APA
Sánchez-Peña, L., Rodríguez-Pallares, S., Aja-Macaya, P., Blanco-Martín, T., González-Pinto, L., Pérez-Rodríguez, G., Le Terrier, C., Portillo-Calderón, I., Recacha, E., Riazzo, C., Vázquez-Ucha, J. C., Beceiro, A., Aracil, B., Oteo-Iglesias, J., Martínez-Martínez, L., Poirel, L., Bou, G., & Arca-Suárez, J. (2025). Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. Antimicrobial Agents and Chemotherapy, 69(9). https://doi.org/10.1128/aac.00533-25
Vancouver
Sánchez-Peña L, Rodríguez-Pallares S, Aja-Macaya P, Blanco-Martín T, González-Pinto L, Pérez-Rodríguez G, et al. Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. Antimicrobial Agents and Chemotherapy. 2025;69(9). doi:10.1128/aac.00533-25
BibTeX
@article{SnchezPea2025,
author = {Sánchez-Peña, Lucía and Rodríguez-Pallares, Salud and Aja-Macaya, Pablo and Blanco-Martín, Tania and González-Pinto, Lucía and Pérez-Rodríguez, Gloria and Le Terrier, Christophe and Portillo-Calderón, Inés and Recacha, Esther and Riazzo, Cristina and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and Aracil, Belén and Oteo-Iglesias, Jesús and Martínez-Martínez, Luis and Poirel, Laurent and Bou, Germán and Arca-Suárez, Jorge},
title = {Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {9},
doi = {10.1128/aac.00533-25}
}
EUVIMED